

Edgar Filing: AMGEN INC - Form 8-K

AMGEN INC
Form 8-K
May 10, 2002

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

May 7, 2002

Date of Report (Date of earliest event reported)

AMGEN INC.

(Exact name of registrant as specified in its charter)

Delaware	000-12477	95-3540776
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

Amgen Inc.	91320-1799
One Amgen Center Drive	(Zip Code)
Thousand Oaks, CA	
(Address of principal executive offices)	

805-447-1000
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On May 7, 2002, Amgen Inc. purchased from F. Hoffman-La Roche Ltd. ("Roche") Roche's rights, assets and business related to Filgrastim and pegfilgrastim in the European Union, Switzerland and Norway. With regard to the EU, the effective date of the purchase is January 1, 2002. Under the terms of the agreement between the parties, Amgen will pay Roche \$137.5 million for this acquisition. Roche will continue as the licensee for Filgrastim and pegfilgrastim in certain countries in Eastern Europe, the Middle East, Africa, Asia and Latin America.

Edgar Filing: AMGEN INC - Form 8-K

The press release announcing the transaction is attached to this Current Report as Exhibit 99.1.

Item 7(c). Exhibits.

See Exhibit Index.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMGEN INC.

Date: May 10, 2002

By: /s/ Richard D. Nanula

Name: Richard D. Nanula
Title: Executive Vice President,
Finance, Strategy and
Communications, and Chief
Financial Officer

2

EXHIBIT INDEX

Exhibit Number -----	Document Description -----
99.1	Press Release dated May 7, 2002.

3